Holen Sie sich die Stockscreener-App
209.36
3.01%
6.11
Vorhandelsmarkt:
210.00
0.64
+0.31%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DHR?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$203.25
Offen:
$203.08
24-Stunden-Volumen:
3.50M
Relative Volume:
0.77
Marktkapitalisierung:
$147.18B
Einnahmen:
$24.78B
Nettoeinkommen (Verlust:
$3.68B
KGV:
40.46
EPS:
5.1743
Netto-Cashflow:
$5.29B
1W Leistung:
+2.01%
1M Leistung:
+3.41%
6M Leistung:
+11.77%
1J Leistung:
+11.04%
1-Tages-Spanne:
$202.62
$209.55
1-Wochen-Bereich:
$199.09
$209.55
52-Wochen-Spanne:
$160.93
$242.80
Danaher Corp Stock (DHR) Company Profile
Firmenname
Danaher Corp
Sektor
Branche
Telefon
(202) 828-0850
Adresse
2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC
Compare DHR vs TMO, NTRA, IQV, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DHR
Danaher Corp
|
209.36 | 140.70B | 24.78B | 3.68B | 5.29B | 5.1743 |
TMO
Thermo Fisher Scientific Inc
|
641.39 | 225.48B | 45.20B | 6.87B | 6.75B | 18.19 |
NTRA
Natera Inc
|
350.78 | 47.41B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
269.67 | 43.09B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
150.27 | 41.42B | 7.23B | 1.41B | 1.09B | 4.979 |
Danaher Corp Stock (DHR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-10-08 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2025-07-11 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-04-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-03-21 | Hochstufung | Goldman | Neutral → Buy |
| 2025-03-14 | Hochstufung | Stifel | Hold → Buy |
| 2025-02-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-19 | Eingeleitet | Guggenheim | Buy |
| 2024-12-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-31 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-17 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-18 | Eingeleitet | HSBC Securities | Hold |
| 2023-12-13 | Fortgesetzt | Wolfe Research | Peer Perform |
| 2023-12-07 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-05-01 | Eingeleitet | SVB Securities | Outperform |
| 2023-04-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-01-05 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-10-24 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-17 | Fortgesetzt | Bernstein | Outperform |
| 2022-07-20 | Eingeleitet | UBS | Buy |
| 2022-06-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-11 | Eingeleitet | Bernstein | Outperform |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-10 | Bestätigt | BofA Securities | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-23 | Bestätigt | Goldman | Buy |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-04-07 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-03-03 | Fortgesetzt | Barclays | Overweight |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-25 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-06-16 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-04-02 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-03-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-02-03 | Bestätigt | Needham | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Fortgesetzt | Stifel | Hold |
| 2019-10-28 | Bestätigt | Needham | Buy |
| 2019-10-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2019-07-19 | Bestätigt | Needham | Buy |
| 2019-06-11 | Eingeleitet | Piper Jaffray | Neutral |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-04-17 | Bestätigt | Needham | Buy |
| 2019-02-28 | Bestätigt | Needham | Buy |
| 2019-02-25 | Hochstufung | Janney | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Needham | Buy |
| 2018-04-20 | Bestätigt | Stifel | Buy |
Alle ansehen
Danaher Corp Aktie (DHR) Neueste Nachrichten
Danaher Corp. stock holds near USD 200 as investors eye earnings and guidance - ad-hoc-news.de
Danaher Corp. stock underperforms Thursday when compared to competitors - MarketWatch
UBS assumes coverage on Danaher stock with buy rating, $250 target - Investing.com Nigeria
Thermo Fisher, Danaher Could Log Mid-Single-Digit Organic Revenue Growth in 2027, UBS Says - Yahoo Finance
Danaher Corp. stock gains support from UBS buy rating and July earnings beat - ad-hoc-news.de
Danaher (DHR) Stock Forecast and Price Target 2026 $DHR - MarketBeat
Danaher stock heads into the open after a 0.87 percent slip - ad-hoc-news.de
Danaher Corp. stock outperforms competitors despite losses on the day - MarketWatch
Danaher stock holds near $207 after Q2 beat - ad-hoc-news.de
Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others - Yahoo Finance UK
Danaher stock heads into the open after a 0.5 percent dip - ad-hoc-news.de
Danaher Corp stock edges lower as investors weigh latest analyst targets and dividend signal - ad-hoc-news.de
Danaher (NYSE:DHR): Is Its Next Move Tied to Inflation Data? - Kalkine Media
Danaher stock holds after Q2 revenue and EPS beat - AD HOC NEWS
Danaher Corp. stock underperforms Friday when compared to competitors - MarketWatch
Danaher Corp. stock trades near 52-week highs as investors digest recent earnings - AD HOC NEWS
Global Multiplex Assays Market 2026 Edition - GlobeNewswire Inc.
Danaher (DHR) Seen Deftly Navigating AI Integration - Yahoo Finance
Baird Adjusts Price Target on Danaher to $238 From $232, Keeps Outperform Rating - marketscreener.com
Danaher (DHR) Stock Trades Near Fair Value But At An Earnings Premium - Yahoo Finance
Danaher Corp. stock outperforms competitors on strong trading day - MarketWatch
Danaher Corp. stock holds steady after recent pullback as investors weigh Q2 2026 results - AD HOC NEWS
Danaher (DHR) Stock Looks Fairly Valued On Cash Flow Yet Overvalued On Earnings - simplywall.st
A Look at Danaher Corp (DHR) After 3.1% Decline -- GF Value $242 - GuruFocus
Danaher Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Danaher Corp Stock (DHR) Moved Down by 3.06% on Sep 1: Facts Behind the Movement - TradingKey
HSBC Adjusts Price Target on Danaher to $250 From $230, Maintains Buy Rating - marketscreener.com
Danaher Corp. stock underperforms Monday when compared to competitors - MarketWatch
Is Danaher Stock Underperforming the Nasdaq? - Barchart.com
Why Danaher (DHR) Remains a Healthcare Compounder to Watch - Yahoo Finance
Danaher Rides on Strength in Biotechnology Segment: Will It Sustain? - Eastern Progress
Danaher president & CEO Rainer Blair sells $12.7 million in company stock - investing.com
Danaher vs. Medtronic: Which Healthcare Recovery Story Has More Upside? - Yahoo Finance
Danaher (NYSE: DHR) holder Blair plans $12.7M stock sale - Stock Titan
Resilient Danaher stock edges higher as institutional buying and analyst support frame the outlook - Ad-hoc-news.de
U.S. Market Edge Lower— Danaher Corporation's Bullish Breakout in Focus - kalkine.ca
6,796 Shares in Danaher Corporation $DHR Bought by Portfolio Design Labs LLC - MarketBeat
17 CAPITAL PARTNERS, LLC's Danaher Corp(DHR) Holding History - GuruFocus
10,799 Shares in Danaher Corporation $DHR Acquired by OVERSEA CHINESE BANKING Corp Ltd - MarketBeat
Somerville Kurt F Purchases Shares of 45,245 Danaher Corporation $DHR - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Makes New Investment in Danaher Corporation $DHR - MarketBeat
932,220 Shares in Danaher Corporation $DHR Bought by Bank of New York Mellon Corp - MarketBeat
Bank of New York Mellon Corp Purchases New Position in Danaher Corporation $DHR - MarketBeat
Danaher Corporation (NYSE:DHR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Danaher Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Danaher (NYSE:DHR) Valuation Debate Deepens After Life Sciences Progress - Kalkine Media
Integrated DNA Technologies Defines the Next Era of DNA Synthesis: Full-Spectrum Capabilities for Speed, Complexity and Scale - StreetInsider
Madison Asset Management LLC Acquires Shares of 448,611 Danaher Corporation $DHR - MarketBeat
Puzo Michael J Makes New Investment in Danaher Corporation $DHR - MarketBeat
Kentucky Farm Bureau Mutual Insurance Co Buys New Position in Danaher Corporation $DHR - MarketBeat
Tocqueville Asset Management L.P. Purchases Shares of 59,318 Danaher Corporation $DHR - MarketBeat
Finanzdaten der Danaher Corp-Aktie (DHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):